CT of the liver and spleen with EOE-13: review of 225 examinations.

Abstract

EOE-13 is an experimental liver-spleen-specific computed tomographic (CT) contrast agent developed at the National Institutes of Health. Experience with this agent in 225 clinical examinations is described. On average, use of EOE-13 increases the attenuation of normal liver by 32.5 H and that of normal spleen by 52.3 H. Tumors in these organs increase only 2.6 H, making them more easily detectable. Most of the iodine in EOE-13 appears to clear from the liver and spleen by 24 hr after injection. No deaths or permanent morbidity have been observed. The complication rate is 3.6%. EOE-13 is valuable for the detection of hepatic and splenic tumors.

• Authors: D L Miller, M Vermess, J L Doppman, R M Simon, P H Sugarbaker, T J O'Leary, G Grimes, D G Chatterji, M Willis
• Journal: AJR. American journal of roentgenology (AJR Am J Roentgenol) Vol. 143 Issue 2 Pg. 235-43 (Aug 1984) ISSN: 0361-803X [Print] United States
• PMID: 6331144 (Publication Type: Journal Article)

Chemical References

• Ethiodized Oil

Topics

• Adult
• Chemical and Drug Induced Liver Injury (etiology)
• Ethiodized Oil (adverse effects)
• Female
• Fever (chemically induced)
• Humans
• Infusions, Parenteral
• Liver (diagnostic imaging, drug effects, pathology)
• Liver Function Tests
• Liver Neoplasms (diagnostic imaging, secondary)
• Lymph Nodes (drug effects, pathology)
• Male
• Middle Aged
• Muscle Rigidity (chemically induced)
• Spleen (diagnostic imaging, drug effects, pathology)
• Splenic Neoplasms (diagnostic imaging)
• Tomography, X-Ray Computed (methods)